UroGen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS

UroGen Pharma (NASDAQ:URGN) released its earnings results on Monday. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09), Zacks reports.

UroGen Pharma Trading Down 3.0%

Shares of URGN stock opened at $10.35 on Monday. The firm’s fifty day simple moving average is $10.64 and its 200 day simple moving average is $10.97. UroGen Pharma has a 1 year low of $8.94 and a 1 year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $477.21 million, a P/E ratio of -3.29 and a beta of 0.66.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of UroGen Pharma in a research report on Monday, April 28th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday. Guggenheim reaffirmed a “buy” rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. The Goldman Sachs Group decreased their price target on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. Finally, LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $32.86.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.